



OFFICE OF INSPECTOR GENERAL U.S. Agency for International Development

MEMORANDUM

DATE: September 26, 2025

TO: Kenneth Jackson
USAID/Deputy Administrator for Management and Resources

Douglas A. Pitkin
USAID/Acting Chief Financial Officer

FROM: David A. McNeil /s/
Director
External Financial Audits Division

SUBJECT: Audit of Incurred Costs for Remote Medicine, Inc., for Fiscal Year Ended December 31, 2022 (3-000-25-024-I)

This memorandum transmits the final audit report on incurred costs submission (ICS) for Remote Medicine, Inc., for Fiscal Year (FY) ended December 31, 2022. The U.S. Agency for International Development (USAID) Office of Acquisition and Assistance, Cost, Audit and Support Division, Contract Audit Management Branch contracted with the independent certified public accounting firm of Tichenor & Associates, LLP, (Tichenor) to conduct the audit. Tichenor stated that it performed its audit in accordance with government auditing standards issued by the Comptroller General of United States. Additionally, Tichenor's examination included evaluating the claimed costs reported in the ICS for compliance with applicable requirements contained in the Federal Acquisition Regulations (FAR), USAID Acquisition Regulation (AIDAR), Cost Accounting Standards (CAS), as applicable, and other specific contract provisions contained in U.S. Government flexibly priced contracts. Tichenor is responsible for the enclosed report and the conclusions expressed in it. We do not express an opinion on whether costs claimed by Remote Medicine in its FY 2022 ICS are accurate, allowable, allocable, and reasonable in accordance with contract terms and applicable Government acquisition regulations.¹

Tichenor's audit objectives were to: (1) determine whether all costs were included in the

¹ We reviewed the audit firm's report for conformity with professional reporting standards. Our desk reviews are typically performed to identify any items needing clarification or issues requiring management attention. Desk reviews are limited to review of the audit report itself and excludes review of the auditor's supporting working papers; they are not designed to enable us to directly evaluate the quality of the audit performed.

proposal to establish final indirect cost rates for the period January 1, 2022, to December 31, 2022, and were allowable in accordance with the cost principles of the FAR and its supplements applicable to the contracts to which the final indirect cost rates applied; (2) ascertain that the proposal did not include any costs which are expressly unallowable under applicable cost principles of the FAR or its supplements; (3) examine Remote Medicine's compliance with the U.S. Government contract or award terms, and applicable Government acquisition regulations, specifically the FAR, AIDAR, 2 Code of Federal Regulations (CFR) 200 Uniform Administrative Requirements, Federal Travel Regulations and/or the Department of State Standard Travel Regulations (DSSR), and Buy-American Act for the Contracting Officer to execute the finalization of allowable contract costs and indirect rates for the fiscal year under review; and (4) examine Remote Medicine's internal controls to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing Tichenor's opinion on management's assertion, but not for the purpose of expressing Tichenor's opinion on the effectiveness of Remote Medicine's internal control. To answer the audit's objectives, Tichenor (1) reviewed Remote Medicine's FY 2022 ICS and reconciled it to the general ledger; (2) reviewed applicable rules, regulations, and guidance; (3) reviewed Remote Medicine's policies and procedures regarding claimed direct and indirect costs; (4) examined, on a test basis, evidence supporting the amounts and disclosures in Remote Medicine's data and records evaluated; and (5) assessed the accounting principles used and significant estimates made by Remote Medicine. Tichenor examined USAID allowable costs of \$48,540,034 for FY 2022.

Tichenor concluded that Remote Medicine prepared its FY 2022 ICS in accordance with applicable Government acquisition regulations in the FAR, the AIDAR, and the DSSR regarding accuracy, allowability, allocability, and reasonableness of incurred costs and is appropriate for the Contracting Officer's use in finalizing of allowable costs and indirect rates for the 2022 fiscal year. Further, Tichenor identified no questioned costs or adjustments to the proposed direct and indirect amounts for contract reimbursement on select unsettled flexibly priced contracts in the ICS submitted by Remote Medicine for the period of January 1, 2022, through December 31, 2022.

OIG does not routinely distribute independent public accounting reports beyond the immediate addressees because a high percentage of these reports contain information restricted from release under the Trade Secrets Act, 18 U.S.C. 1905 and Freedom of Information Act Exemption Four, 5 U.S.C. 552(b)(4) ("commercial or financial information obtained from a person that is privileged or confidential"). In addition, USAID OIG has determined that this transmittal memo and the enclosed report are not subject to notification and reporting requirements under Section 5274 of the National Defense Authorization Act.²

² The James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 Pub. L. No. 117-263, § 5274. Please direct related inquiries to oignotice_ndaa5274@usaid.gov.